Physician profile
Tara L Viggiani
NPI 1831527795
$12,046.73
in general payments reported to CMS, 2019-2025
47 companies · $3,154 in 2025
The $3,154 reported for 2025 was more than what 96% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,880 · 2022: $1,931 · 2023: $2,417 · 2024: $2,665 · 2025: $3,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,791 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,791.02 |
| Education | $445.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,568.15 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $1,088.38 | 2021-2025 | Tagrisso, Imfinzi, Lynparza |
| Amgen INC. | $875.38 | 2021-2023 | Lumakras, Xgeva, Nplate |
| E.R. Squibb & Sons, L.L.C. | $822.51 | 2021-2025 | Opdivo |
| Abbvie INC. | $742.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $725.41 | 2021-2025 | |
| Taiho Oncology, INC. | $595.19 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $540.66 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $451.95 | 2021-2025 | |
| Array Biopharma INC | $385.94 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Eisai INC. | $381.66 | 2021-2025 | |
| Emd Serono, INC. | $354.66 | 2022-2025 | Tepmetko, Bavencio |
| Takeda Pharmaceuticals U.S.A., INC. | $339.69 | 2021-2025 | Alunbrig, Fruzaqla, Exkivity |
| Janssen Biotech, INC. | $317.34 | 2024-2025 | Rybrevant, Erleada, Balversa |
| Astellas Pharma US INC | $306.18 | 2023-2025 | Vyloy |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $292.20 | 2021-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $268.77 | 2021-2025 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $218.62 | 2023-2024 | Krazati |
| Pfizer INC. | $160.81 | 2021-2024 | |
| Incyte Corporation | $152.92 | 2021-2025 | Monjuvi, Zynyz, Jakafi |
| Blueprint Medicines Corporation | $150.61 | 2021-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.31 | 2021-2025 | Gilotrif |
| G1 Therapeutics, INC. | $111.49 | 2022-2023 | Cosela |
| Jazz Pharmaceuticals INC. | $100.93 | 2023-2025 | |
| Genzyme Corporation | $100.22 | 2021-2023 | |
| Seagen INC. | $99.00 | 2021-2024 | |
| Tersera Therapeutics LLC | $86.68 | 2021-2025 | Xermelo |
| Deciphera Pharmaceuticals INC. | $82.74 | 2021-2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $82.45 | 2023-2025 | Monoferric, Cosela |
| Lilly USA, LLC | $82.04 | 2021-2023 | Retevmo, Jaypirca, Verzenio |
| Foundation Medicine, INC. | $41.25 | 2022 | |
| Novocure INC. | $41.11 | 2025 | Optune Lua (Novottf-200t) |
| Servier Pharmaceuticals LLC | $41.03 | 2023-2024 | |
| Exelixis INC. | $32.70 | 2021-2025 | Cabometyx |
| Beone Medicines USA, INC. | $32.48 | 2025 | Tevimbra, Brukinsa |
| Janssen Scientific Affairs, LLC | $30.22 | 2024-2025 | Rybrevant |
| Cumberland Pharmaceuticals, INC. | $28.31 | 2024 | Sancuso |
| Helsinn Therapeutics (U.S.), INC. | $26.65 | 2021-2022 | |
| Fennec Pharmaceuticals, INC. | $25.51 | 2025 | Fyarro |
| Glaxosmithkline, LLC. | $20.60 | 2025 | Jemperli |
| Beigene USA, INC. | $17.90 | 2024 | Tevimbra |
| Alkermes, INC. | $17.59 | 2024 | Aristada, Lybalvi |
| Stemline Therapeutics INC. | $17.27 | 2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $16.97 | 2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $16.92 | 2022 | |
| Acrotech Biopharma INC. | $16.70 | 2025 | Ryzneuta |
| Aimmune Therapeutics, INC. | $14.99 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Viggiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.